APO RESEARCH · REPORT
Prostate Cancer Diagnostics
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Product & engineering
Understand the product.
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
Selected research
Industry Growth & Trends
Global Prostate Cancer Diagnostics Industry Growth and Trends Forecast to 2032
Market perspective
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
According to APO Research, the global Prostate Cancer Diagnostics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Read the full market overview
Report Scope
This report provides a structured, data-driven view of the global Prostate Cancer Diagnostics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Prostate Cancer Diagnostics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Prostate Cancer Diagnostics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Prostate Cancer Diagnostics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Prostate Cancer Diagnostics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Prostate Cancer Diagnostics Market by Company
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Prostate Cancer Diagnostics Segment by Type
Tumor Biomarker Tests
Imaging
Biopsy
Other
Prostate Cancer Diagnostics Segment by Application
Age Below 55
Age 55-75
Age Above 75
Prostate Cancer Diagnostics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Prostate Cancer Diagnostics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tumor Biomarker Tests
- Imaging
- Biopsy
- Other
Applications
- Age Below 55
- Age 55-75
- Age Above 75
Companies covered
- OPKO
- Genomic Health
- Abbott
- Beckman Coulter
- Siemens Healthcare
- bioMeriux
- Roche
- MDx Health
- DiaSorin
- Myriad Genetics
- Ambry Genetics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Prostate Cancer Diagnostics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Prostate Cancer Diagnostics Market Size by Region (2021-2032)
- 1.4.1 Global Prostate Cancer Diagnostics Market Size by Region (2021-2026)
- 1.4.2 Global Prostate Cancer Diagnostics Market Size by Region (2027-2032)
- 1.5 Key Regions Prostate Cancer Diagnostics Market Size (2021-2032)
- 1.5.1 North America Prostate Cancer Diagnostics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Prostate Cancer Diagnostics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Prostate Cancer Diagnostics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Prostate Cancer Diagnostics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Prostate Cancer Diagnostics Market Size Growth Rate (2021-2032)
2 Prostate Cancer Diagnostics Market by Type
- 2.1 Type Introduction
- 2.1.1 Tumor Biomarker Tests
- 2.1.2 Imaging
- 2.1.3 Biopsy
- 2.1.4 Other
- 2.2 Global Prostate Cancer Diagnostics Market Size by Type
- 2.2.1 Global Prostate Cancer Diagnostics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Prostate Cancer Diagnostics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Prostate Cancer Diagnostics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Prostate Cancer Diagnostics Market Size by Regions
- 2.3.1 North America Prostate Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Prostate Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Prostate Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Prostate Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Prostate Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
3 Prostate Cancer Diagnostics Market by Application
- 3.1 Type Introduction
- 3.1.1 Age Below 55
- 3.1.2 Age 55-75
- 3.1.3 Age Above 75
- 3.2 Global Prostate Cancer Diagnostics Market Size by Application
- 3.2.1 Global Prostate Cancer Diagnostics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Prostate Cancer Diagnostics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Prostate Cancer Diagnostics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Prostate Cancer Diagnostics Market Size by Regions
- 3.3.1 North America Prostate Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Prostate Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Prostate Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Prostate Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Prostate Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Prostate Cancer Diagnostics Industry Trends
- 4.2 Prostate Cancer Diagnostics Industry Drivers
- 4.3 Prostate Cancer Diagnostics Industry Opportunities and Challenges
- 4.4 Prostate Cancer Diagnostics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Prostate Cancer Diagnostics Revenue (2021-2026)
- 5.2 Global Prostate Cancer Diagnostics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Prostate Cancer Diagnostics Key Company Headquarters & Area Served
- 5.4 Global Prostate Cancer Diagnostics Company, Product Type & Application
- 5.5 Global Prostate Cancer Diagnostics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Prostate Cancer Diagnostics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Prostate Cancer Diagnostics Players Market Share by Revenue in 2025
- 5.6.3 2025 Prostate Cancer Diagnostics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 OPKO
- 6.1.1 OPKO Company Information
- 6.1.2 OPKO Business Overview
- 6.1.3 OPKO Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
- 6.1.5 OPKO Recent Developments
- 6.2 Genomic Health
- 6.2.1 Genomic Health Company Information
- 6.2.2 Genomic Health Business Overview
- 6.2.3 Genomic Health Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
- 6.2.5 Genomic Health Recent Developments
- 6.3 Abbott
- 6.3.1 Abbott Company Information
- 6.3.2 Abbott Business Overview
- 6.3.3 Abbott Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
- 6.3.5 Abbott Recent Developments
- 6.4 Beckman Coulter
- 6.4.1 Beckman Coulter Company Information
- 6.4.2 Beckman Coulter Business Overview
- 6.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
- 6.4.5 Beckman Coulter Recent Developments
- 6.5 Siemens Healthcare
- 6.5.1 Siemens Healthcare Company Information
- 6.5.2 Siemens Healthcare Business Overview
- 6.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
- 6.5.5 Siemens Healthcare Recent Developments
- 6.6 bioMeriux
- 6.6.1 bioMeriux Company Information
- 6.6.2 bioMeriux Business Overview
- 6.6.3 bioMeriux Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
- 6.6.5 bioMeriux Recent Developments
- 6.7 Roche
- 6.7.1 Roche Company Information
- 6.7.2 Roche Business Overview
- 6.7.3 Roche Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
- 6.7.5 Roche Recent Developments
- 6.8 MDx Health
- 6.8.1 MDx Health Company Information
- 6.8.2 MDx Health Business Overview
- 6.8.3 MDx Health Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
- 6.8.5 MDx Health Recent Developments
- 6.9 DiaSorin
- 6.9.1 DiaSorin Company Information
- 6.9.2 DiaSorin Business Overview
- 6.9.3 DiaSorin Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
- 6.9.5 DiaSorin Recent Developments
- 6.10 Myriad Genetics
- 6.10.1 Myriad Genetics Company Information
- 6.10.2 Myriad Genetics Business Overview
- 6.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
- 6.10.5 Myriad Genetics Recent Developments
- 6.11 Ambry Genetics
- 6.11.1 Ambry Genetics Company Information
- 6.11.2 Ambry Genetics Business Overview
- 6.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
- 6.11.5 Ambry Genetics Recent Developments
7 North America
- 7.1 North America Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 7.3 North America Prostate Cancer Diagnostics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 8.3 Europe Prostate Cancer Diagnostics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Prostate Cancer Diagnostics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 10.3 South America Prostate Cancer Diagnostics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Prostate Cancer Diagnostics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst